A grand disconnect between government policy and industry reality is killing the golden goose of the UK’s life sciences sector. Despite its immense potential to generate wealth and innovation, the industry is being starved of the conditions it needs to thrive, leading to a predictable and tragic decline.
The evidence of this slow death is stark. The goose has stopped laying golden eggs, with MSD canceling a £1 billion research facility. Other companies are flying the coop; Eli Lilly has paused its UK expansion, and Sanofi is reducing its footprint, halving its clinical trials and halting new investment.
The cause of death would be listed as a series of long-term, systemic failures. The government has failed to provide adequate “feed” in the form of competitive drug prices and sufficient healthcare spending. Instead, it has imposed a punitive “clawback” tax that takes back a significant portion of the value created. This disconnect between rhetoric and reality has become fatal.
The UK’s nest of academic talent remains a key asset, but it cannot sustain a flock that is being actively driven away. To revive the golden goose, the government must radically change its approach, creating a nurturing and supportive environment. Without this, it will be responsible for killing one of its most valuable economic creatures.